PMC9911898_01
Patient at baseline (A-D) and after 4 weeks (E-H) of treatment with tildrakizumab.
CCID-16-369-g0001.jpg
PMC9911898_01_CCID-16-369-g0001.jpg
f0001
At 4-week follow-up, PASI100 (reduction of PASI of 100%) response was rapidly reached, with a complete skin clearance (Figure 1).